TH.TO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 22:59):

Stats
Dzisiejszy wolumen	9 815.00
Średni wolumen	25 025.00
Kapitalizacja rynkowa	82.30M
EPS	$0 ( 2024-04-10 )
Następna data zysków	( $-0.0400 ) 2024-07-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.24
ATR14	$0.0100 (0.56%)

Theratechnologies Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Theratechnologies Inc Finanse

Annual	2023
Przychody:	$81.76M
Zysk brutto:	$62.13M (75.99 %)
EPS:	$-0.910

FY	2023
Przychody:	$81.76M
Zysk brutto:	$62.13M (75.99 %)
EPS:	$-0.910

FY	2022
Przychody:	$80.06M
Zysk brutto:	$53.78M (67.17 %)
EPS:	$-0.500

FY	2021
Przychody:	$69.82M
Zysk brutto:	$46.56M (66.69 %)
EPS:	$-0.340

Financial Reports:

No articles found.

Theratechnologies Inc

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.